TARS
Tarsus Pharmaceuticals Inc
NASDAQ: TARS · HEALTHCARE · BIOTECHNOLOGY
$60.67
-2.29% today
Updated 2026-04-29
Market cap
$2.61B
P/E ratio
—
P/S ratio
5.78x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$39 – $85
Volume
0.6M
Tarsus Pharmaceuticals Inc (TARS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | $2.39M | $58.32M | $171.97M | $178.91M | $227.86M | $265.49M | $376.99M |
| Cash & equivalents | — | — | — | — | — | — | — |
| Current assets | $2.38M | $58.03M | $170.66M | $175.95M | $225.38M | $256.13M | $356.70M |
| Total liabilities | $3.74M | $64.32M | $5.99M | $12.18M | $34.96M | $68.50M | $152.46M |
| Current liabilities | $179000.00 | $819000.00 | $5.39M | $11.48M | $15.43M | $36.94M | $80.61M |
| Long-term debt | — | — | — | — | $19.43M | $29.82M | $71.84M |
| Shareholder equity | — | — | — | — | — | — | — |
| Retained earnings | $-1.36M | $-6.03M | $-32.84M | $-46.67M | $-108.76M | $-244.66M | $-360.21M |
| Accounts receivable | $4000.00 | $36000.00 | $20000.00 | $92000.00 | $3.58M | $17.71M | $48.06M |
| Inventory | — | $20000.00 | — | $175.68M | $4.76M | $3.11M | $2.62M |
| Goodwill | — | — | — | — | — | — | — |